Company Overview

Inotiv, Inc. is a U.S.-based contract research organization that provides nonclinical and preclinical drug discovery and development services to pharmaceutical, biotechnology, medical device, and government customers. The company operates within the life sciences, biopharmaceutical services, and research models industries, supporting clients from early discovery through regulatory-enabling studies. Its core revenue drivers are laboratory research services, toxicology and safety assessment studies, and the supply of research models and related services.

The company was formed through the combination of legacy Inotiv and Envigo RMS, with Envigo RMS acquired in 2021, significantly expanding scale and capabilities. This acquisition transformed Inotiv into an integrated provider spanning discovery services and research models. In 2024, Inotiv and certain subsidiaries filed for Chapter 11 bankruptcy protection and continue to operate as a going concern under restructuring, with the company’s equity trading on the OTC market under the symbol NOTVQ. This restructuring marked a major inflection point in the company’s evolution.

Business Operations

Inotiv operates primarily through two major business segments: Discovery & Preclinical Services and Research Models & Services. The Discovery & Preclinical Services segment generates revenue by providing in vitro and in vivo pharmacology, toxicology, safety assessment, and regulatory support services required for IND- and NDA-enabling programs. The Research Models & Services segment supplies purpose-bred laboratory animals, genetically engineered models, and associated husbandry and technical services.

Operations are conducted across domestic and international facilities, with significant laboratory and breeding infrastructure. The company controls specialized research assets including animal colonies, testing laboratories, and proprietary scientific workflows. Its operating structure includes multiple subsidiaries under the Inotiv umbrella, notably Envigo RMS, which remains central to the research models business. Data on current joint ventures or newly formed partnerships is inconclusive based on available public sources following the Chapter 11 filing.

Strategic Position & Investments

Inotiv’s strategic direction has focused on offering an integrated, end-to-end nonclinical solution that reduces complexity and timelines for drug developers. Prior to restructuring, growth initiatives emphasized cross-selling discovery services to research model customers and expanding capabilities in biologics, gene therapy, and specialized toxicology studies. The acquisition of Envigo RMS was the most significant strategic investment, materially increasing revenue scale but also contributing to elevated leverage.

During the Chapter 11 process, strategic priorities shifted toward balance sheet restructuring, operational stabilization, and selective divestitures or cost rationalization. Public disclosures indicate continued involvement in emerging therapeutic areas such as cell and gene therapy research support, though the extent of new capital investment in these areas post-filing is not fully verifiable. Data inconclusive based on available public sources regarding post-restructuring acquisition activity.

Geographic Footprint

Inotiv maintains operations primarily in North America and Europe, with its corporate headquarters in the United States. The company operates research laboratories, breeding facilities, and service centers across multiple U.S. states and the United Kingdom, supporting both domestic and international clients. These regions account for the majority of revenue and operational capacity.

The company also serves customers in Asia-Pacific and other international markets through direct operations and export of research models and services. While Inotiv has a global customer base, its international operational footprint is concentrated in developed life sciences markets, with limited evidence of large-scale infrastructure investments outside the U.S. and Europe based on publicly available information.

Leadership & Governance

Inotiv’s leadership team is responsible for navigating the company through restructuring while maintaining scientific and operational continuity. The company was not founded by a single individual but grew through mergers and acquisitions within the contract research sector. Governance during the Chapter 11 process includes oversight by the board of directors and court supervision.

Key executives include:

• Robert Leasure – President & Chief Executive Officer
• David Windley – Chief Financial Officer
• Jeffrey Van Horn – Chief Operating Officer

Public statements from leadership emphasize a strategic vision centered on operational discipline, customer retention, and long-term viability as an integrated nonclinical services provider. Information on recent leadership changes or interim appointments beyond these roles is inconclusive based on available public sources.